Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abuse Potential of Tozadenant in Recreational Polydrug Users
NCT03200080Phase 1Terminated
- Sponsor
- Biotie Therapies
- Start
- Sep 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tozadenant in Parkinson's disease (PD) (6 arms), sponsored by Biotie Therapies. Primary endpoint: Drug Liking at 24 hours. Started Sep 2017; status: terminated.
02
Drugs
tozadenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03200080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03200080.